Table 2.
Clinical response of cancers harboring wild-type p53 to chemotherapy.
| Cancer type [Ref.] | Treatment | Incidence (%) | Response rate (%) | 5-Year survival rate (%) |
|---|---|---|---|---|
| Bladder [123] | Various | 49 | Not given | 45 |
| Breast [85] | Paclitaxel | 67 | 45 | Not given |
| Choroid plexus [84] | Various | 50 | Not given | 100 |
| CLL [87] | Chl/flu/cyc | 92 | 83 | 59 |
| Germ cell [88,113] | Platinum | ~100 | ~90 | ~90 |
| Mesothelioma [117–121] | Various | ~90 | 5–33 | 0–14 |
| NSCLC [114,115,125] | Various | 68 | 6–43 | 0–13 |
| Ovarian [116,124] | Paclitaxel/platinum | 40 | 47 | 43 |
| RCC [122,126,127] | Various | ~90 | Not given | ~30 |
Abbreviations: Chl/flu/cyc, chlorambucil/fludarabine/cyclophosphamide; CLL, chronic lymphocytic leukemia; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.